Chris Key
Studies suggest that soluble activin receptor type IIB (ActRIIB) proteins like ACE 031, which are IgG1-Fc, may be further studied in biological approaches. In mice, the ACE-031 peptide is believed to influence muscle size and other growth factors by blocking the normal production of myostatin, a protein secreted in muscle cells.
ACE 031 Peptide: What is it?
Research indicates that the research protein ACE-031 is a recombinant fusion protein that may join two parts of the ActRIIB receptor and the antibody in mice. By decreasing the off signal, which stops muscle synthesis, the muscles become more resilient.
Studies have suggested that AGE-031 may inhibit the secretion of these ligands, leading to enhanced muscle growth. ACE-031’s properties have been speculated in several animal experiments to considerably enhance muscular mass and strength. Research also indicated that it may protect against neuromuscular diseases and muscle atrophy.
Although ACE-031 protein has not been licensed for human ingestion, laboratory studies have evaluated the peptide in animal and cell culture-based research in the context of neuromuscular diseases and muscle mass.
ACE 031 Peptide and Muscle Cells
Acceleron CEO John Knopf, Ph.D., said ACE-031 has “great potential” as an approach for neuromuscular illnesses in mice. These diseases include muscular dystrophy and amyotrophic lateral sclerosis (ALS).
Loss of muscle mass is a direct cause of mortality in illnesses like amyotrophic lateral sclerosis and muscular dystrophy, which may affect murine models. The possible function of ACE-031 in halting muscular atrophy is becoming clearer to researchers.
Animal models of renal failure and cancer cachexia have suggested lessening of muscle cell loss when exposed to myostatin-blocking substances such as ACE 031. Further research has purported that they may improve insulin sensitivity, decrease inflammation, decrease fat mass, and stimulate bone repair and mineralization. No matter the expression of fiber types, ACE 031 has been hypothesized to enhance muscle hypertrophy in mouse model research.
ACE 031 Peptide and Neuromuscular Disease
The results of the Phase 1 experimental study for ACE-031 suggested that the peptide might act to increase lean mass; this was announced recently by Acceleron Pharma, Inc., a biopharmaceutical company that develops novel approaches to promote the growth of cells and tissues, such as muscle, red blood cells, and bone.
“We are truly delighted that this ACE-031 Phase 1 experimental study yielded such promising data and evident biological [potential] on muscle, bone, and fat, all after only one concentration of ACE-031,” stated Matthew Shermice, M.D., Acceleron’s Chief Medical Officer. Lean mass, muscle volume, bone formation, and biomarkers for fat mass were all hypothesized to be quickly, steadily, and concentration-dependently raised by ACE-031. These findings have prompted researchers to launch a Phase 1 multiple-concentration experiment of ACE-031, and they are excited about further developing this compound for the context of neuromuscular disorders in mice.
ACE 031 Peptide Potential
Researchers now have a potent tool in the shape of ACE-031, a soluble version of the activin receptor type IIB (ActRIIB), to investigate the function of the activin/myostatin pathway in muscle development and growth. Compared to other research tools, this peptide is believed to have many potential impacts, such as a high affinity for activin and myostatin, a strong inhibitory impact on these growth factors, and the possibility of evaluating the peptide to investigate illnesses related to muscle wasting and other disorders.
When tested on animal models of muscular atrophy and wasting illnesses, ACE-031 suggested positive data. Data from various animal models, including monkeys and mice, suggests that ACE-031 may potentially prevent muscle atrophy and enhance muscular development. With the help of ACE-031, which is believed to block the action of myostatin and activin, researchers may potentially learn more about the causes of these diseases and maybe find new mitigation targets.
ACE 031 Peptide: Cellular and Molecular Biology
ACE-031 is believed to be a potential instrument for studying the molecular and cellular processes that may control muscle expansion and contraction. By blocking myostatin and activin, ACE-031 may help us understand how these growth factors may influence muscular structure in animal models.
ACE 031 Peptide Development Potential
Due to its unusual characteristics, ACE-031 may exert some potential in muscle tissue atrophy disorders. Few approaches exist for these disorders; however, investigations purport that ACE-031 may provide a new strategy targeting the activin/myostatin pathway. The results may have wider implications for the understanding and approach of muscular atrophy and wasting illnesses in general.
ACE 031 Peptide Synthesis
The extracellular domain of ActRIIB is fused to an immunoglobulin Fc domain during the creation and modification of ACE-031. A persistent and soluble receptor type that may bind and neutralize myostatin and activin is produced by this fusion. Thanks to recent developments in peptide synthesis and protein engineering, ACE-031 is now a research compound available for investigating the activin/myostatin pathway thanks to its proposed stability, affinity, and potency.
Scientists interested in peptides for sale in the USA are encouraged to visit the Core Peptides website for the highest-quality and most affordable research compounds.
References
[i] “Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys With Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial,” Craig Campbel, Hugh J McMillan, Jean K Mah, Mark Tarnopolsky, Kathryn Selby, Ty McClure, Dawn M Wilson, Matthew L Shermice, Diana Escolar, Kenneth M Attie https://pubmed.ncbi.nlm.nih.gov/27462804/
[ii] “ACE-031 for the Treatment of Duchenne Muscular Dystrophy,” https://www.clinicaltrialsarena.com/projects/ace031forthetreatmen/
[iii] “Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial,” https://www.flagshippioneering.com/press/acceleron-pharmas-ace-031-increases-lean-body-mass-phase-1-single-dose-clinical-trial
[iv] Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607.
[v] Canter D, Frank GJ, Knapp LE, McLain RW. The safety profile of quinapril: is there a difference among ACE inhibitors? Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII39-42. doi: 10.1002/clc.4960131408. PMID: 2189620.
Comments